FY2024 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for IQVIA in a research note issued to investors on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings per share of $10.13 for the year, up from their previous forecast of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

IQV has been the topic of a number of other research reports. Robert W. Baird reduced their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday. Leerink Partners reiterated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Finally, Morgan Stanley decreased their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $257.60.

IQVIA Stock Down 0.3 %

IQV stock opened at $200.37 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business’s fifty day moving average price is $213.40 and its two-hundred day moving average price is $224.61. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The stock has a market capitalization of $36.37 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 2.07 and a beta of 1.49.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the third quarter worth $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the second quarter worth about $29,000. International Assets Investment Management LLC bought a new position in IQVIA in the 2nd quarter worth about $32,000. Finally, Avior Wealth Management LLC boosted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.